McKesson Corporation MCK recently announced a definitive agreement to acquire Precision Medicine Group, LLC, a global provider of clinical research and biopharma commercialization services. The transaction is expected to strengthen McKesson’s oncology and multispecialty strategy by enhancing its clinical research and commercialization capabilities.
McKesson chairman and CEO Brian Tyler said the acquisition represents an important advancement in the company’s oncology and multispecialty strategy. Precision Medicine Group’s complementary capabilities are expected to strengthen McKesson’s clinical research and commercialization services, improve clinical trial execution and expand the company’s range of clinical service offerings.
MCK Stock Trend Following the News
MCK stock has lost 0.9% since the announcement on Tuesday. Year to date, the stock has gained 9.3% compared with the industry’s 7.1% growth and the S&P 500’s 11.6% rise.
The acquisition is expected to strengthen McKesson’s oncology and multispecialty business by expanding clinical research and biopharma commercialization capabilities. Precision Medicine Group’s established relationships across the biopharma ecosystem could create opportunities for McKesson to serve customers across a broader range of needs. Over time, the acquisition could support recurring revenue growth, improve McKesson’s exposure to higher-value healthcare services and strengthen its competitive position in the rapidly evolving life sciences market.
MCK currently has a market capitalization of $105.52 billion.
Image Source: Zacks Investment Research
More on the News
Precision Medicine Group provides integrated services and technology-enabled solutions that help biotechnology and pharmaceutical companies advance therapies from early development through commercialization. Its offerings include biomarker intelligence, laboratory services, global clinical research, market access consulting and commercialization support, enabling life sciences companies to bring new treatments from molecules to market.
Precision Medicine Group CEO Margaret Keegan said joining McKesson provides an opportunity to extend the company’s clinical and commercial expertise for the benefit of customers, partners and patients. The partnership will broaden the range of capabilities available to biopharma companies across the development and commercialization process.
Financial Outlook of Acquisition
McKesson will acquire Precision Medicine Group for approximately $2.25 billion. The transaction remains subject to customary closing conditions, including regulatory clearances. Once the transaction closes, Precision Medicine Group will become part of McKesson’s Oncology & Multispecialty segment.
Industry Prospects Favoring the Market
Going by data provided by Grandview Research, the global healthcare contract research organization (CRO) market is predicted to be valued at $63.7 billion in 2026 and is expected to witness a CAGR of 7.5% through 2033.
Factors such as the increasing investments in drug development, growing research and development activities, rising regulatory requirements, globalization of clinical trials and increasing outsourcing of research activities by biopharmaceutical companies are expected to support market growth.
Other News
Recently, McKesson exited the first quarter of fiscal 2027, wherein both earnings and revenues surpassed the estimates. Growth was broad-based, led by North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Specialty distribution remained a key driver. The company sold a 13% minority stake in Medical-Surgical Solutions to Apollo Funds for $1.25 billion and secured a $2.25 billion term loan. McKesson announced Wellverse as the future standalone company’s name, with operations under the new identity expected to begin in January 2027.
McKesson Corporation Price
McKesson Corporation price | McKesson Corporation Quote
MCK’s Zacks Rank & Key Picks
Currently, MCK carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical GMED, Veracyte VCYT and West Pharmaceutical WST.
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
McKesson Corporation (MCK): Free Stock Analysis Report
West Pharmaceutical Services, Inc. (WST): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
Veracyte, Inc. (VCYT): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).